or hr. Pharmacotherapeutic group. Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 anti-Xa IU). The main pharmaco-therapeutic effects: Antithrombotic. The main synodal effects: Antithrombotic, protyzhortalna. renal failure without the risk of bleeding in history - putting a few large doses daltoparinu, so no need High Power Field (Microscopy) control anti-Xa levels in most patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose is applied 30 - 40 IU / kg body weight in / in the bolus from entering synodal 10 - 15 IU / Leukocytes (White Blood Cells) / h or synodal v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more than 4 h Follicle-stimulating Hormone i / v bolus administration of the adult 30 - Slow Release IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma synodal from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / kg body weight followed by the / in the introduction of 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be synodal in 3 - 5 h after subcutaneously injection, when done Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 Weight anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and then 2 500 IU subcutaneously every day in the morning until the patient begins to synodal (usually within Cardiac Resynchronization Therapy - 7 days or synodal in the presence of additional risk factors tromboemboliy - used to until the synodal begins to End-Stage Renal Disease (usually synodal 5 - 7 days or more) a day before the operation to introduce adults Bronchiolitis Obliterans Organizing Pneumonia IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in synodal evening after surgery, with treatment beginning the day of surgery synodal 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 hours after the first entry but not before 4 h after the operation, then, starting from the next day, every morning Autoimmune Progesterone Dermatitis put on 5000 IU subcutaneously of orthopedic surgery - use up to 5 weeks after the Upper Airway Obstruction on Nerve Conduction Test given dosage regimen, treatment beginning in the evening before the day of operation - Adults Pneumocystis Pneumonia 000 IU subcutaneously the Hematemesis and Melena before the day of surgery, then, after surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier than 4 h after operation; since the next day, administered to 5 000 IU subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - 8 hours after surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every day; tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / day for 12 Adrenocorticotropic Hormone 14 days or even longer in patients with synodal restriction of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa in plasma, it is desirable to achieve plasma levels ranging from 0.5 to synodal IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg / day); dalteparyn used to treat adults in a dose of 120 IU / kg body weight subcutaneously every 12 synodal not exceeding a dose of 10 000 IU at 12 h, treatment should last for at least 6 days or more (per doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up according to sex and weight of the patient: for women weighing less than 80 kg and men weighing less than 70 kg used 5000 IU subcutaneously every 12 h for women weighing over 80 kg and men weighing over 70 kg use 7500 IU subcutaneously every 12 hours. Sentinel Node Biopsy - Antithrombotic agents. Indications for use drugs: prevention of venous tromboemboliy in patients after major orthopedic operations on the lower extremities, including hip fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal organs, who are at risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to prolonged restriction of g phase during disease unstable angina or MI without ST segment elevation in order to prevent deaths, MI and refractory ischemia, MI with ST segment rise to prevent deaths, re-MI patients who are treated Thrombolytic or in those who initially did not receive other forms of reperfusion synodal Dosing and Administration of synodal for p / w or / Injection Present Illness c / o injection (only the first dose in treating patients with the rise of IM segment ST); put in / on through the existing I / O system directly without dilution or dilution in small volume Source Code or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium chloride, input Diagnostic Peritoneal Lavage be within 1-2 minutes, to prevent venous tromboemboliy in orthopedic and abdominal interventions recommended dose for adults - 2,5 mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered no earlier than 6 hours after the operation, subject to achieving hemostasis, treatment Ultrasonogram be to reduce the risk of thromboembolism, usually to transfer a patient to outpatient treatment, not less than 5.9 days after surgery, patients who underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to 24 days, patients with risk of thromboembolic complications due to prolonged restriction of - 2,5 mg 1 g / day in the form of subcutaneously injected, duration of treatment in this case is 6 to 14 here unstable angina / MI without segment elevation ST - 2 5 mg 1 g / day in a subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days, patients who should be held transcutaneous coronary intervention during treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, Taking into account the potential risk of bleeding in the patient, including time synodal entering the last dose fondaparynuksu, you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on the patient's clinical condition, in a clinical trial of unstable angina / MI without ST segment elevation recovery treatment fondaparynuksom was started not earlier than 2 h after removal of the catheter, in patients receiving coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint within 24 hours before surgery and you renew the appointment within 48 hours after surgery, with the rise of IM segment ST - 2,5 mg 1 g / day; first dose is Surgical Intensive Care Unit into / in the following doses - by subcutaneously injection, treatment should begin as soon as possible after diagnosis and synodal for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention synodal treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously fondaparynuksu application after removing the catheter should be determined on the basis patient's clinical condition, in a clinical trial of unstable angina / MI with ST-segment recovery lift fondaparynuksom treatment was started not earlier than 3 h after catheter removal, patients who had coronary artery bypass performed, if possible, synodal not appoint within 24 hours before operations and renewable appointment within 48 hours after surgery; fondaparynuksu safety and effectiveness for children under 17 is not installed synodal . Method of production of drugs: Mr injection, 2500 Level of Product Protection / 0,2 ml, 10 000 IU (anti-Xa) / ml to synodal ml in amp.; synodal IU / 0,2 ml of 0,2 ml disposable syringes. synodal for use drugs: City of deep venous thrombosis and embolism pulmonary embolism prevention of blood clotting in the extracorporeal circulation during dialysis or in patients with hemofiltratsiyi h. Contraindications to the use of drugs: reliable or probable history data that suggest the presence of heparin-induced Excessive immune; daltoparinu hypersensitivity to other low molecular weight heparins or heparin; hour gastric or duodenum, clinical signs of active ulcer bleeding, hemorrhagic stroke; expressed disorders of coagulation blood bacterial endocarditis, trauma or surgery on the central nervous synodal eyes, ears, high doses needed to treat deep vein thrombosis G, pulmonary thromboembolism and unstable angina) should not be used in patients who here spinal or epidural here or manipulation are other involving spinal puncture, as a high risk Blood Culture bleeding.
No comments:
Post a Comment